18 and older, any sex, with Intervention Engagement and Retention. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants Attending at Least 50% of SessionsPrimary· nine weeks
We will test if different intervention delivery strategies will result in a clinically and statistically important intervention attendance with a minimum of 50% of participants attending at least 50% of the intervention
Group
Value
95% CI
Supervision/Paid/Open Group
8
Supervision/Paid/Closed Group
6
Supervision/Not Paid/Open Group
1
Supervision/Not Paid/Closed Group
4
Not Under Supervision/Paid/Open Group
19
Not Under Supervision/Paid/Closed Group
12
Not Under Supervision/Not Paid/Open Group
5
Not Under Supervision/Not Paid/Closed Group
4
Adverse events — posted to ClinicalTrials.gov
Time frame: 6 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Rates of alcohol and substance misuse (ASM) in low-income, predominantly African American communities are similar to the general population. However, ASM has greater consequences (e.g., higher incarceration and HIV infection rates) for residents in these communities. We developed and optimized Community Wise (CW), a multi-level manualized behavioral intervention to decrease ASM frequency in a population of self-identified men with histories of substance use disorder (SUD) and incarceration (SUD) in Essex County, New Jersey (NJ), U.S. We propose a study to: 1) identify strategies to improve attendance and reduce ASM, and 2) to test feasibility and acceptability of CW among self-identified men and women with a history of SUD living in marginalized communities. We will achieve these aims by conducting a 23 full factorial experiment informed by MOST and CBPR. This study will identify efficient, scalable, and sustainable strategies to improve attendance and hence, maximize the interventions' effect in reducing ASM.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Other University of Illinois at Urbana-Champaign trials
Trials by the same sponsor.
NCT07477067 — Exercise and Protein Efficiency in T2D
· NA
· recruiting
NCT07367854 — Diet Synergy in Muscle Protein Synthesis
· NA
· not yet recruiting
NCT07323862 — Assessment of a Method to Improve Cochlear Implant Users' Speech Perception in Noisy Environments While Maintaining Thei
· NA
· not yet recruiting
NCT07020741 — Stable Isotopes- Adults With Obesity
· NA
· recruiting
NCT07167680 — Fall Prevention Among People With Spinal Cord Injury and Multiple Sclerosis Who Use Wheelchairs and Scooters
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Illinois at Urbana-Champaign
Last refreshed: 2 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05934591.